Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Younger age at onset of colorectal cancer is associated with increased patient's delay

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  1. Antidepressant Use in Siblings of Children With Cancer: A Danish Population-Based Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Smartphone App to Self-Monitor Nausea During Pediatric Chemotherapy Treatment: User-Centered Design Process

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Improved Survival of Children, Adolescents, and Young Adults With Head and Neck Soft Tissue Sarcomas in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Thorsten Langer
  • Eva Clemens
  • Linda Broer
  • Lara Maier
  • André G Uitterlinden
  • Andrica C H de Vries
  • Martine van Grotel
  • Saskia F M Pluijm
  • Harald Binder
  • Benjamin Mayer
  • Annika von dem Knesebeck
  • Julianne Byrne
  • Eline van Dulmen-den Broeder
  • Marco Crocco
  • Desiree Grabow
  • Peter Kaatsch
  • Melanie Kaiser
  • Claudia Spix
  • Line Kenborg
  • Jeanette F Winther
  • Catherine Rechnitzer
  • Henrik Hasle
  • Tomas Kepak
  • Anne-Lotte F van der Kooi
  • Leontien C Kremer
  • Jarmila Kruseova
  • Stefan Bielack
  • Benjamin Sorg
  • Stefanie Hecker-Nolting
  • Claudia E Kuehni
  • Marc Ansari
  • Martin Kompis
  • Heleen van der Pal
  • Ross Parfitt
  • Dirk Deuster
  • Peter Matulat
  • Amelie Tillmanns
  • Wim J E Tissing
  • Jörn D Beck
  • Susanne Elsner
  • Antoinette Am Zehnhoff-Dinnesen
  • Marry M van den Heuvel-Eibrink
  • Oliver Zolk
  • PanCareLIFE consortium
Vis graf over relationer

BACKGROUND: Irreversible sensorineural hearing loss is a common side effect of platinum treatment with the potential to significantly impair the neurocognitive, social and educational development of childhood cancer survivors. Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in a pharmacogenetic guideline. The aim of this cross-sectional cohort study was to confirm the genetic associations in a large pan-European population and to evaluate the diagnostic accuracy of the genetic markers.

METHODS: Eligibility criteria required patients to be aged less than 19 years at the start of chemotherapy, which had to include cisplatin and/or carboplatin. Patients were assigned to three phenotype categories: no, minor and clinically relevant hearing loss. Fourteen variants in eleven candidate genes (ABCC3, OTOS, TPMT, SLC22A2, NFE2L2, SLC16A5, LRP2, GSTP1, SOD2, WFS1 and ACYP2) were investigated. Multinomial logistic regression was performed to model the relationship between genetic predictors and platinum ototoxicity, adjusting for clinical risk factors. Additionally, measures of the diagnostic accuracy of the genetic markers were determined.

RESULTS: 900 patients were included in this study. In the multinomial logistic regression, significant unique contributions were found from SLC22A2 rs316019, the age at the start of platinum treatment, cranial radiation and the interaction term [platinum compound]∗[cumulative dose of cisplatin]. The predictive performance of the genetic markers was poor compared with the clinical risk factors.

CONCLUSIONS: PanCareLIFE is the largest study of cisplatin-induced ototoxicity to date and confirmed a role for the polyspecific organic cation transporter SLC22A2. However, the predictive value of the current genetic candidate markers for clinical use is negligible, which puts the value of clinical factors for risk assessment of cisplatin-induced ototoxicity back into the foreground.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Cancer
Vol/bind138
Sider (fra-til)212-224
Antal sider13
ISSN0959-8049
DOI
StatusUdgivet - okt. 2020

Bibliografisk note

Copyright © 2020 Elsevier Ltd. All rights reserved.

ID: 62272326